CA3013457A1 - Mesenchymal stem cells as vaccine adjuvants and methods for using the same - Google Patents

Mesenchymal stem cells as vaccine adjuvants and methods for using the same Download PDF

Info

Publication number
CA3013457A1
CA3013457A1 CA3013457A CA3013457A CA3013457A1 CA 3013457 A1 CA3013457 A1 CA 3013457A1 CA 3013457 A CA3013457 A CA 3013457A CA 3013457 A CA3013457 A CA 3013457A CA 3013457 A1 CA3013457 A1 CA 3013457A1
Authority
CA
Canada
Prior art keywords
protein
virus
adjuvant
vaccine
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3013457A
Other languages
English (en)
French (fr)
Inventor
Joshua M. Hare
Ana Marie LANDIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of CA3013457A1 publication Critical patent/CA3013457A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3013457A 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same Pending CA3013457A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291350P 2016-02-04 2016-02-04
US62/291,350 2016-02-04
PCT/US2017/016200 WO2017136539A1 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Publications (1)

Publication Number Publication Date
CA3013457A1 true CA3013457A1 (en) 2017-08-10

Family

ID=58261704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013457A Pending CA3013457A1 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Country Status (11)

Country Link
US (2) US11975068B2 (https=)
EP (2) EP4316497A3 (https=)
JP (3) JP7814090B2 (https=)
KR (1) KR20180105705A (https=)
AU (2) AU2017213812B2 (https=)
CA (1) CA3013457A1 (https=)
ES (1) ES2960206T3 (https=)
IL (1) IL260858B (https=)
SG (1) SG11201806587RA (https=)
WO (1) WO2017136539A1 (https=)
ZA (2) ZA201805159B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112641938A (zh) * 2020-11-22 2021-04-13 翁炳焕 一种dna重组干细胞载体新冠疫苗

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020166063A1 (ja) * 2019-02-15 2020-08-20 大和薬品株式会社 フレイル改善方法およびフレイル改善食品
CN111568927A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节记忆b细胞数量的应用
JP2023540096A (ja) 2020-09-08 2023-09-21 ロングエバーオン インコーポレイテッド アロジェニック間葉系幹細胞によるアルツハイマー病の治療
US20220218817A1 (en) * 2021-01-08 2022-07-14 Vitro Biopharma, Inc. Immune modulation by mesenchymal stem cells
CN117999082A (zh) 2021-07-26 2024-05-07 美商生命科学有限公司 间充质干细胞在治疗青少年左心发育不良综合征中的用途
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US8554280B2 (en) 2010-03-23 2013-10-08 Ebay Inc. Free-form entries during payment processes
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
CN104138391B (zh) 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112641938A (zh) * 2020-11-22 2021-04-13 翁炳焕 一种dna重组干细胞载体新冠疫苗

Also Published As

Publication number Publication date
JP2026012755A (ja) 2026-01-27
JP2023036949A (ja) 2023-03-14
EP3411050B1 (en) 2023-09-27
WO2017136539A1 (en) 2017-08-10
AU2017213812B2 (en) 2024-04-04
SG11201806587RA (en) 2018-09-27
EP4316497A2 (en) 2024-02-07
JP2019509264A (ja) 2019-04-04
ES2960206T3 (es) 2024-03-01
US20190038742A1 (en) 2019-02-07
AU2024204598A1 (en) 2024-07-18
ZA202000574B (en) 2021-08-25
EP3411050A1 (en) 2018-12-12
ZA201805159B (en) 2020-10-28
EP4316497A3 (en) 2024-05-01
US11975068B2 (en) 2024-05-07
IL260858B (en) 2022-04-01
AU2017213812A1 (en) 2018-08-16
IL260858A (en) 2018-10-31
US20240252627A1 (en) 2024-08-01
KR20180105705A (ko) 2018-09-28
JP7814090B2 (ja) 2026-02-16

Similar Documents

Publication Publication Date Title
US20240252627A1 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
US20260027158A1 (en) Methods of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity
KR101788885B1 (ko) 세포 요법에 사용하기 위한 방법 및 조성물
CN106167789B (zh) 低氧处理的间充质干细胞及其应用
ES2987001T3 (es) Tratamiento de la caquexia usando células de fibroblasto y productos de las mismas
Ivanova et al. Anti-Asialo GM1 treatment during secondary Toxoplasma gondii infection is lethal and depletes T cells
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
Habiela The Role of Follicular Dendritic Cells and Persisting Foot-And-Mouth Disease Virus Antigens as Determinants of Immune Responses to the Virus
Russell Inducing IL-1β to increase vaccine efficacy
JP2008536511A (ja) ＣＤ８Ｔ細胞の活性化方法｛ＭｅｔｈｏｄＦｏｒＡｃｔｉｖａｔｉｎｇＣＤ８ＴＣｅｌｌｓ｝
NZ794290A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
US20210171581A1 (en) Immune activation triggered by filovirus proteins and polypeptides
NZ794292A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
Singleton B cell responses to respiratory viral infections

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220120

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250915

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260316